

<https://doi.org/10.46344/JBINO.2025.v14i04.05>

SUSTAINABLE FINANCING FOR HIV PREVENTION: PUBLIC-PRIVATE PARTNERSHIPS IN AFRICA

Emmanuel Ifeanyi Obeagu

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

Email : emmanuelobeagu@yahoo.com

ABSTRACT

Sustainable financing for HIV prevention remains a significant challenge in sub-Saharan Africa, where the burden of the epidemic is most acute. Traditional funding sources, including international aid, have proven insufficient to meet the growing demand for prevention programs. Public-private partnerships (PPPs) have emerged as a viable model to bridge this financing gap, combining the strengths of both public and private sectors to mobilize resources, improve service delivery, and foster innovation. These partnerships facilitate the development of sustainable, scalable interventions that address the complex socio-economic and healthcare challenges of the region. In Africa, PPPs in HIV prevention have shown promising results through enhanced resource mobilization, the introduction of new technologies, and the strengthening of local healthcare systems. Examples from countries such as South Africa, Kenya, and Uganda illustrate how collaboration between governments, private corporations, and non-governmental organizations has expanded access to prevention services, including testing, counseling, and antiretroviral treatment. Furthermore, PPPs contribute to policy development, capacity building, and the creation of more efficient and transparent financing mechanisms, all of which are crucial for long-term HIV prevention efforts.

Keywords: *HIV prevention, sustainable financing, public-private partnerships, Africa, healthcare systems*

Introduction

The HIV/AIDS epidemic remains one of the most significant public health challenges in sub-Saharan Africa, where over 60% of the global HIV-positive population resides. Despite substantial international investments and substantial progress in prevention, treatment, and care, the region continues to face substantial barriers to scaling up HIV prevention efforts. One of the primary challenges is the lack of sustainable financing mechanisms, with many countries dependent on international aid and donor funding, which can be unstable and unpredictable. The need for a more sustainable and diversified funding model to support long-term HIV prevention strategies is critical to reducing new infections and mitigating the impact of HIV on affected communities [1-2]. Traditional financing for HIV prevention, which primarily relies on international donors, has limitations that hinder the consistent delivery of services, especially in resource-constrained environments. Donor funding, while essential, often fluctuates based on global economic conditions, changing political priorities, and donor fatigue. Additionally, many African governments face fiscal constraints, and the lack of sufficient domestic resources for health systems further exacerbates the problem. To address these challenges, there is a growing recognition of the need to engage multiple sectors, including the private sector, in the fight against HIV/AIDS. Public-private partnerships (PPPs) have emerged as an innovative solution to help bridge this financing gap, by combining the resources and expertise of both the public and private sectors to create more

effective, sustainable HIV prevention programs [3-4].

Public-private partnerships (PPPs) have the potential to enhance HIV prevention efforts by fostering collaboration between governments, private companies, and civil society organizations. These partnerships allow for the pooling of resources, expertise, and technology, thereby improving the efficiency of HIV programs and reducing costs. In the context of Africa, where infrastructure and healthcare systems are often underfunded and overstretched, PPPs can provide much-needed support in terms of funding, innovation, and logistical expertise. Furthermore, the private sector's involvement can lead to the development of new, cost-effective solutions that enhance prevention strategies, such as mobile health services, diagnostic tools, and innovative outreach campaigns [5-6]. PPP models vary widely across Africa, but their shared characteristic is the blending of government oversight with private sector innovation. Successful models leverage private sector investment in exchange for a return on investment, either through direct financial returns or through long-term social benefits. These partnerships can also enable the scaling up of HIV prevention programs, expanding access to services such as HIV testing, counseling, and prevention education, particularly in remote or underserved regions. In addition to financing, PPPs play an important role in strengthening healthcare infrastructure, building local capacity, and improving the delivery of prevention services at the community level [7-8]. The integration of the private sector

into HIV prevention programs also brings the potential for innovative financing mechanisms. For instance, social impact bonds (SIBs) and blended financing approaches provide ways to attract private investment by reducing risk and offering measurable outcomes that align with both public health and business goals. Corporate social responsibility (CSR) initiatives, where companies contribute to health programs as part of their ethical commitment, also play a role in sustaining HIV prevention programs. By creating a diversified funding model, PPPs offer a long-term, sustainable solution that can overcome the limitations of traditional funding sources, while also promoting greater accountability and performance-based results [9-10].

The Role of Public-Private Partnerships in HIV Prevention

Public-private partnerships (PPPs) have emerged as a transformative model for HIV prevention in sub-Saharan Africa, offering a collaborative framework to address the complex and multifaceted challenges of the epidemic. In regions with limited resources and strained healthcare infrastructures, PPPs bring together the unique strengths of both the public and private sectors, facilitating the pooling of resources, knowledge, and expertise. These partnerships not only provide financial support but also introduce innovation, efficiency, and sustainability to HIV prevention efforts, which are crucial for combating the continued spread of the virus [11-12]. A key role of PPPs in HIV prevention is resource mobilization. Traditional funding mechanisms, such as international aid and government

allocations, are often insufficient to meet the rising demand for comprehensive prevention services. By engaging the private sector, PPPs attract additional funding, which is crucial for scaling up HIV testing, counseling, and awareness campaigns. For example, partnerships with pharmaceutical companies have enabled the provision of affordable antiretroviral drugs (ARVs), while collaborations with technology firms have facilitated the development of mobile health applications and platforms to increase outreach and early diagnosis. Through such collaborations, PPPs expand the financial base for HIV prevention and ensure the continuity of services despite the unpredictability of donor funding [13-14].

Innovation is another critical contribution of PPPs to HIV prevention. The private sector often brings cutting-edge technologies and new approaches that can significantly enhance prevention efforts. This includes the development of diagnostic tools, mobile health interventions, and rapid testing methods that increase accessibility to HIV services, especially in rural or hard-to-reach areas. For instance, companies that specialize in mobile technology have partnered with governments to create mobile apps for HIV education and real-time health data sharing, enabling individuals to access testing and treatment information directly from their phones. These innovations help reduce barriers to HIV prevention, particularly in settings where healthcare resources are scarce or where stigma associated with HIV testing may deter people from seeking care [15-16]. Moreover, PPPs help improve

healthcare system capacity, which is essential for the long-term success of HIV prevention programs. By leveraging private sector expertise in logistics, supply chain management, and service delivery, PPPs can streamline the implementation of prevention initiatives. This is particularly important in ensuring the consistent supply of HIV-related medicines, prevention materials (e.g., condoms, pre-exposure prophylaxis), and healthcare services. Additionally, private sector partners often assist with training and capacity-building efforts for healthcare professionals, improving the quality of care provided to people at risk of HIV. By strengthening healthcare systems, PPPs make HIV prevention programs more efficient, responsive, and sustainable [16-17].

In terms of policy development, PPPs have the potential to influence national and regional HIV prevention strategies. Governments can benefit from the expertise and advocacy of private sector partners in shaping policies that prioritize HIV prevention in national health agendas. For example, partnerships between governments and private entities can promote the inclusion of HIV prevention in corporate social responsibility (CSR) programs or advocate for favorable tax policies that incentivize private sector involvement in public health initiatives. By aligning public and private interests, PPPs create a shared commitment to addressing the HIV epidemic and ensure that HIV prevention remains a central component of public health policy [18-19]. PPPs contribute to the creation of a more sustainable financing model for HIV prevention. Traditional donor funding can

fluctuate due to changes in global economic conditions or political priorities. However, PPPs introduce alternative, more stable sources of funding, including investments from private companies, social impact bonds (SIBs), and blended financing models. These innovative financing mechanisms offer a way to attract private capital into HIV prevention efforts, which is critical for ensuring that programs are not only effective but also sustainable in the long term. By providing a diversified financial base, PPPs help reduce dependence on external donors and create a more resilient financing model for HIV prevention [20-21].

Benefits of Public-Private Partnerships

Public-private partnerships (PPPs) offer several key benefits that significantly enhance HIV prevention efforts, particularly in resource-limited settings like sub-Saharan Africa. These partnerships combine the strengths of both the public and private sectors, leading to more effective, efficient, and sustainable HIV prevention strategies. Below are the primary benefits of PPPs in the context of HIV prevention:

1. Increased Financial Resources

One of the most significant advantages of PPPs is the ability to mobilize additional financial resources for HIV prevention. Traditionally, HIV programs in sub-Saharan Africa have relied heavily on international donor funding, which can be unpredictable and insufficient. PPPs help to diversify the sources of funding by incorporating private sector investments, which can be more stable and less susceptible to political or economic changes. Private companies can

contribute through direct investments, philanthropic efforts, and corporate social responsibility (CSR) initiatives, providing a much-needed financial buffer that strengthens the sustainability of HIV prevention programs [22].

2. Innovation and Technological Advancements

The private sector is often at the forefront of technological innovation and can introduce cutting-edge solutions to improve HIV prevention efforts. Through PPPs, companies specializing in healthcare technologies, mobile applications, diagnostic tools, and digital health solutions can collaborate with governments and nonprofits to enhance the reach and effectiveness of HIV prevention programs. For example, mobile phone applications can be used for HIV education, risk assessment, or even remote counseling, making services more accessible in remote areas. Innovative diagnostic tools can also facilitate early detection and encourage regular testing, further reducing the spread of the virus. These innovations help overcome barriers such as limited healthcare infrastructure, stigma, and geographical constraints, ensuring that prevention services are accessible to all [23].

3. Improved Service Delivery and Healthcare System Strengthening

Through PPPs, private sector expertise in logistics, supply chain management, and healthcare service delivery can greatly enhance the efficiency and effectiveness of HIV prevention programs. The private sector's involvement in the procurement and distribution of essential HIV prevention tools, such as condoms, pre-exposure

prophylaxis (PrEP), and antiretroviral drugs (ARVs), can streamline operations and reduce delays. Furthermore, partnerships with private entities can help build the capacity of healthcare workers by providing training programs, technical support, and continuous professional development. This contributes to improving the overall quality of HIV prevention services, ensuring that they are delivered in a timely, efficient, and patient-centered manner [24].

4. Expansion of Access to HIV Prevention Services

PPP models can facilitate the expansion of HIV prevention services to underserved or remote populations that might otherwise have limited access to care. For example, collaborations with mobile health companies can result in mobile clinics that travel to rural areas, bringing HIV testing, education, and treatment to individuals who might otherwise face geographical, financial, or logistical barriers. By leveraging the reach and infrastructure of the private sector, PPPs make it possible to scale up HIV prevention efforts to rural and hard-to-reach communities, ensuring that more people receive timely services and information [25].

5. Strengthened Policy Development and Advocacy

Public-private partnerships also play an important role in influencing policy development and advocacy for HIV prevention. By collaborating with the private sector, governments can gain valuable insights and expertise on issues such as healthcare financing, regulatory frameworks, and service delivery models. Private sector involvement can also

amplify advocacy efforts to prioritize HIV prevention in national health policies. For instance, businesses with a large presence in a region may be able to advocate for policies that integrate HIV prevention into employee healthcare programs or sponsor public awareness campaigns. These policy interventions help secure long-term commitment from both public and private stakeholders to address the HIV epidemic comprehensively [26].

6. Sustainability and Long-Term Impact

PPPs help create a more sustainable model for HIV prevention by combining the financial and operational strengths of both the public and private sectors. This collaborative approach reduces reliance on donor funding, which can fluctuate, and creates a more predictable funding model through private sector involvement. Furthermore, PPPs often introduce performance-based financing mechanisms, such as social impact bonds (SIBs), that ensure accountability and measure the outcomes of HIV prevention interventions. These focuses on results help ensure that HIV prevention programs are not only effective in the short term but are sustainable in the long run, leading to lasting improvements in public health [27].

Challenges of Public-Private Partnerships (PPPs) in HIV Prevention

While public-private partnerships (PPPs) offer numerous benefits in addressing the HIV epidemic, they are not without their challenges. The success of these partnerships depends on navigating a complex array of obstacles that can hinder their effectiveness and sustainability. Below

are some of the key challenges faced by PPPs in HIV prevention:

1. Regulatory and Policy Barriers

One of the primary challenges of PPPs in HIV prevention is the regulatory and policy environment in which they operate. In many African countries, the legal frameworks governing public health and private sector involvement may not be conducive to the smooth operation of PPPs. Inadequate regulations or unclear policies can create confusion, delays, or reluctance among private sector companies to invest in HIV prevention programs. Furthermore, some governments may lack the capacity to create and enforce policies that ensure private sector contributions align with public health goals. In some cases, the political landscape may present barriers to the acceptance and implementation of PPPs, particularly if there is resistance to involving the private sector in public health initiatives or a lack of political will to engage in such partnerships [28].

2. Equitable Distribution of Resources

A significant concern with PPPs is ensuring that resources are distributed equitably across all communities, particularly those in rural or underserved areas. Private sector partners may be more inclined to focus on urban areas or regions with higher population densities, where the potential for financial returns is greater. This could result in the marginalization of rural communities, where the HIV burden may be equally high but access to care is limited. Additionally, private sector involvement might prioritize profit-driven motives over social impact, potentially leading to unequal access to prevention

services. Ensuring that PPPs are designed with equity in mind is essential to avoid exacerbating existing disparities in HIV prevention and care [29].

3. Sustainability of Financing

While PPPs can provide a more diversified and stable source of funding compared to traditional donor-based models, there are concerns about the long-term sustainability of private sector investments in HIV prevention. Private companies may have short-term financial goals, and their commitment to social causes can fluctuate due to changes in economic conditions or corporate priorities. For instance, during economic downturns or changes in corporate leadership, companies may reduce or withdraw their investments in public health programs. This can create instability in HIV prevention efforts, leaving vulnerable populations at risk. Ensuring that PPPs are built on long-term, mutually beneficial partnerships is critical to maintaining consistent funding for HIV prevention services [30].

4. Accountability and Transparency

A significant challenge in PPPs is ensuring accountability and transparency in the management of resources and the delivery of services. The involvement of multiple stakeholders—governments, private companies, and civil society—can complicate the monitoring and evaluation of HIV prevention programs. Without clear governance structures and transparent reporting mechanisms, there is a risk of mismanagement or corruption, especially if private companies are primarily driven by profit motives. Establishing clear roles and responsibilities, as well as robust mechanisms for monitoring, evaluation,

and auditing, is essential to ensuring that resources are used effectively and that the objectives of the partnership are met [31].

5. Alignment of Objectives

For a PPP to succeed, the objectives of both the public and private sectors must be aligned. However, there is often a fundamental difference in priorities between the two sectors. While the public sector is focused on maximizing public health outcomes and ensuring equitable access to HIV prevention services, the private sector may prioritize profitability and market expansion. This misalignment of goals can lead to conflicts in decision-making, with the private sector potentially pushing for interventions that are more commercially viable rather than those that are most beneficial for the public. Effective communication and shared understanding of the partnership's goals are crucial to mitigating these conflicts and ensuring that both sectors work toward a common objective [32].

6. Cultural and Social Barriers

In many African societies, HIV is highly stigmatized, and addressing this stigma is critical to the success of any HIV prevention program. Public-private partnerships may struggle to navigate cultural and social barriers that hinder the acceptance of HIV-related services, particularly in conservative or rural communities. Private companies may not have the cultural sensitivity or local knowledge needed to engage with communities effectively, while governments may face challenges in overcoming societal stigma and misinformation about HIV. Overcoming these barriers requires culturally competent

approaches and strong community involvement to ensure that prevention programs are accepted and effectively implemented [33].

7. Risk of Marketization of Health Services

Another challenge in PPPs is the potential for the commercialization or "marketization" of health services. While private sector involvement can increase efficiency and innovation, it can also lead to the privatization of essential services, which may limit access for the most vulnerable populations. If HIV prevention services become profit-driven, this could create barriers to access, especially for low-income individuals who cannot afford to pay for services. Ensuring that PPPs prioritize public health goals over profit-making is essential to avoid turning essential HIV prevention services into commodities that are only available to those who can pay [34].

8. Lack of Local Capacity and Expertise

In some cases, the private sector may lack the local knowledge and experience necessary to effectively implement HIV prevention programs in diverse African contexts. This is especially true for multinational companies that may not have an in-depth understanding of the specific challenges and needs of local populations. To mitigate this, PPPs must involve local actors, such as non-governmental organizations (NGOs), community health workers, and local healthcare providers, to ensure that programs are culturally appropriate and effectively address local needs. Additionally, building local capacity through training and skill development is essential for ensuring the sustainability of

HIV prevention efforts beyond the duration of the partnership [35].

Innovative Financing Mechanisms for Sustainable HIV Prevention

The global fight against HIV has made significant progress, yet substantial challenges remain in sustaining prevention efforts, particularly in low-resource settings. Traditional funding models, such as government budgets and donor assistance, have been insufficient to fully address the scale of the epidemic, especially in sub-Saharan Africa. To achieve sustainable HIV prevention, innovative financing mechanisms are necessary. These mechanisms can help mobilize additional resources, reduce dependence on fluctuating donor funding, and promote long-term sustainability. Below are some of the most innovative financing approaches currently being explored or implemented to ensure the continued success of HIV prevention programs [36].

1. Social Impact Bonds (SIBs)

Social Impact Bonds (SIBs) are a novel financing mechanism that involves private investors funding HIV prevention programs with the understanding that their investment will be repaid with a return if specific, measurable outcomes are achieved. In this model, governments or non-governmental organizations (NGOs) outline clear objectives for HIV prevention, such as reducing new HIV infections or increasing access to prevention services. Private investors provide upfront capital to fund these activities, and if the program meets its agreed-upon outcomes, the government or a donor agency repays the

investors with interest. SIBs align the interests of all stakeholders and provide a mechanism to scale up effective HIV prevention programs without relying solely on traditional government or donor funding. This results-based financing model can help ensure that interventions are both effective and cost-efficient, creating incentives for achieving measurable health outcomes [37].

2. Public-Private Partnerships (PPPs)

As previously discussed, Public-Private Partnerships (PPPs) are an essential component of innovative financing for HIV prevention. By combining resources, expertise, and infrastructure from both the public and private sectors, PPPs can scale up HIV prevention efforts and bring additional funding to the table. These partnerships can include pharmaceutical companies, mobile health providers, insurance companies, and other private sector entities that contribute funding or services in exchange for mutually agreed-upon outcomes, such as improved access to prevention tools or the development of innovative HIV prevention technologies. Moreover, private sector investments can stimulate market-driven approaches, such as the development of new HIV prevention technologies (e.g., pre-exposure prophylaxis, or PrEP) and the distribution of these tools to high-risk populations. Through a shared financial commitment, PPPs can create sustainable funding streams that help reduce the burden on public health systems [38].

3. Crowdfunding for HIV Prevention

Crowdfunding is an increasingly popular method for raising funds for social causes, including HIV prevention. This model

involves collecting small amounts of money from a large number of individuals through online platforms. Crowdfunding can help mobilize resources for specific HIV prevention projects, such as condom distribution programs, community-based testing, or educational campaigns. This mechanism not only raises funds but also raises awareness of HIV-related issues, engages communities, and empowers individuals to take part in global health efforts. Crowdfunding can be particularly effective for grassroots organizations and smaller-scale interventions that might not otherwise have access to large donors or governmental funds. However, it is crucial to develop effective strategies to engage donors and ensure accountability in the use of funds [39].

4. Health Impact Investment Funds

Health Impact Investment Funds (HIIFs) are specialized investment vehicles designed to attract private capital for health-related projects, including HIV prevention. These funds pool resources from institutional investors, such as pension funds, foundations, and high-net-worth individuals, to support large-scale, high-impact HIV prevention initiatives. HIIFs are distinct from traditional venture capital or private equity funds in that they focus on delivering measurable social outcomes in addition to financial returns. The investments can be directed toward programs that address the broader social determinants of HIV, such as education, access to healthcare, and social services. HIIFs have the potential to provide long-term, sustainable funding for HIV prevention programs, particularly in settings where government budgets are

limited and donor funding is uncertain. Additionally, HIFs can be designed to reward programs that meet both health and financial objectives, ensuring that investments are used efficiently [40-41].

5. Taxation and Levies on Harmful Products

Innovative taxation mechanisms can be explored as a sustainable means of financing HIV prevention efforts. Governments can introduce taxes or levies on products and behaviors that contribute to the spread of HIV, such as tobacco, alcohol, or gambling. These "sin taxes" generate additional revenue that can be earmarked for HIV prevention and treatment programs. For example, tobacco taxes have been used in several countries to fund public health initiatives, and similar approaches could be applied to HIV prevention efforts. By taxing behaviors that contribute to the HIV epidemic, governments can create a sustainable, non-reliant revenue stream that supports prevention efforts. While such taxes might be controversial, they align the interests of public health with fiscal policy and encourage healthier behaviors among the population. Ensuring that the revenue from these taxes is used transparently for HIV prevention is critical to maintaining public support [42-43].

6. Blockchain Technology and Cryptocurrency

Blockchain technology and cryptocurrency offer novel opportunities for financing HIV prevention programs in a transparent, decentralized, and secure manner. Through blockchain, it is possible to create new financial models that allow individuals and organizations to contribute to HIV prevention efforts in a way that

ensures the traceability of funds and accountability for their use. Cryptocurrency donations, particularly through platforms that accept Bitcoin or other cryptocurrencies, can facilitate cross-border donations and access to funds that can be used for global HIV prevention efforts. Furthermore, blockchain technology can help monitor the distribution of HIV-related resources (such as medications or condoms) by ensuring transparency in the supply chain and reducing opportunities for corruption. By integrating blockchain technology into HIV financing models, stakeholders can ensure that contributions are used efficiently and reach the intended beneficiaries [44-46].

7. Microfinance and Social Loans for HIV Prevention

Microfinance institutions (MFIs) can also play a role in financing HIV prevention initiatives, particularly by providing low-interest loans or grants to small-scale projects that address HIV prevention. For example, MFIs could fund local entrepreneurs who distribute condoms, provide HIV-related education, or deliver community-based HIV testing services. Microfinance could also be used to support individuals living with HIV, helping them access resources for maintaining their health, such as affordable medications or nutritional supplements. This model allows local communities to take ownership of HIV prevention efforts and ensures that funds are used in culturally appropriate and context-specific ways. Social loans or impact bonds, similar to SIBs, could be issued to support these initiatives, with investors receiving returns based on

the success of the HIV prevention programs they support [47-49].

Conclusion

Sustainable financing is crucial for the continued success of HIV prevention efforts, particularly in sub-Saharan Africa, where the HIV burden remains high. While traditional funding sources have played a significant role, innovative financing mechanisms offer a promising path to ensuring long-term, consistent support for prevention programs. Approaches such as Social Impact Bonds (SIBs), Public-Private Partnerships (PPPs), crowdfunding, Health Impact Investment Funds (HIIFs), and tax levies on harmful products provide diverse and adaptable solutions to address funding gaps. Additionally, emerging technologies like blockchain and microfinance open new avenues for resource mobilization and ensure greater transparency and local ownership in HIV prevention efforts. The integration of these innovative financing models allows for a more sustainable, equitable, and effective response to the HIV epidemic, addressing both the immediate and long-term needs of affected populations. However, these mechanisms must be carefully designed to ensure they complement existing systems and are tailored to local contexts, particularly in areas with significant social and economic challenges. Moreover, fostering strong partnerships among governments, the private sector, non-governmental organizations, and affected communities is essential to the success of these approaches.

References

1. Payagala S, Pozniak A. The global burden of HIV. *Clinics in dermatology*. 2024; 42(2):119-127.
2. Stelzle D, Rangaraj A, Jarvis JN, Razakasoa NH, Perrin G, Low-Beer D, Doherty M, Ford N, Dalal S. Prevalence of advanced HIV disease in sub-Saharan Africa: a multi-country analysis of nationally representative household surveys. *The Lancet Global Health*. 2025; 13(3):e437-146.
3. Ten Brink D, Martin-Hughes R, Bowring AL, Wulan N, Burke K, Tidhar T, Dalal S, Scott N. Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study. *The Lancet HIV*. 2025; 12(5):e346-354.
4. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res*. 2023; 10(10):56-62.
5. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024; 4(1):38-44.
6. Gao TY, Zhao LK, Liu X, Li HY, Ma YT, Fang W, Wang XL, Zhang C. Disease burden of AIDS in last 30-year period and its predicted level in next 25-years based on the global burden disease 2019. *BMC Public Health*. 2024; 24(1):2384.
7. Carter A, Zhang M, Tram KH, Walters MK, Jahagirdar D, Brewer ED, Novotney A, Lasher D, Mpolya EA, Vongpradith A, Ma J. Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. *The Lancet HIV*. 2024; 11(12):e807-822.
8. Li XC, Zhang YY, Zhang QY, Liu JS, Ran JJ, Han LF, Zhang XX. Global burden of viral

- infectious diseases of poverty based on Global Burden of Diseases Study 2021. *Infectious Diseases of Poverty*. 2024; 13(05):53-67.
9. Yermukhanova L, Kuzembayev M, Salkhanova A, Narymbayeva N, Tazhiyeva A, Makhanbetkulova DN, Afshar A. Exploring socio-economic dimensions in HIV research: a comprehensive bibliometric analysis (1992–2024). *Global Health Action*. 2025; 18(1):2474787.
 10. Mobaderi T, Kazemnejad A, Salehi M. Clustering and modeling joint-trajectories of HIV/AIDS and tuberculosis mortality rates using bayesian multi-process latent growth model: A global study from 1990 to 2021. *BMC Infectious Diseases*. 2025; 25(1):330.
 11. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024; 2(1):34-46.
 12. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine*. 2023; 102(47):e35910.
 13. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page*: <http://www.journalijar.com>. 2024;12(01).
 14. Xu F, Xiong Y, Gu M, Wan L, Wang Y. Interventions to prevent mother-to-child transmission in breastfeeding mothers with HIV: a systematic review and meta-analysis of randomized controlled trials. *Revista do Instituto de Medicina Tropical de São Paulo*. 2024; 66:e45.
 15. Yin X, Wang W, Chen H, Mao Q, Han G, Yao L, Gao Q, Gao Y, Jin J, Sun T, Qi M. 2025, July Edition | www.jbino.com | Innovative Association Publication
 - Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China. *Nature Medicine*. 2024; 30(2):455-462.
 16. Astawesegn FH, Mannan H, Stulz V, Conroy E. Understanding the uptake and determinants of prevention of mother-to-child transmission of HIV services in East Africa: Mixed methods systematic review and meta-analysis. *Plos one*. 2024; 19(4):e0300606.
 17. Sari TB, Sudirham. Prevention of mother-to-child transmission of HIV infection in Nigeria: what are the barriers?. *Journal of Public Health*. 2025; 47(1):e171-172.
 18. Tshivhase L, Setshedi FM, Moyo I. Approaches for prevention of mother-to-child transmission of HIV services during coronavirus disease 2019. *Health SA Gesondheid*. 2024; 29(1).
 19. de Lannoy LH, Fuentes A, Santos PC, Coelho R, Miranda AE. HIV in pregnant woman and children: Mother- to- child transmission of HIV in the Brazilian land border from 2010 to 2021. *International Journal of Gynecology & Obstetrics*. 2024; 166(1):90-98.
 20. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024; 2(1):1-5.
 21. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*. 2024; 2(3):111-7.
 22. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015; 4(4):906-10.

- 23.Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015; 2(11):268-271.
- 24.Parindra IK, Menap M, Khalik LA. Optimization of Hospital Health Services: Insights from Recent Literature. Bioscientist: Jurnal Ilmiah Biologi. 2024; 12(2):1636-1655.
- 25.Leitch S, Wei Z. Improving spatial access to healthcare facilities: an integrated approach with spatial analysis and optimization modeling. Annals of Operations Research. 2024; 341(2):1057-1074.
- 26.World Health Organization. Strategy for optimizing national routine health information systems: strengthening routine health information systems to deliver primary health care and universal health coverage. World Health Organization; 2024.
- 27.Tripathi S, Sukumaran R, Cook TS. Efficient healthcare with large language models: optimizing clinical workflow and enhancing patient care. Journal of the American Medical Informatics Association. 2024; 31(6):1436-1440.
- 28.Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine. 2023; 102(47):e36342.
- 29.Obeagu EI, Obeagu GU, Buhari HA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. International Journal of Innovative and Applied Research, 2024; 12 (1) 12-26
- 30.Airaoje OK, Ogunbola O, Falobi F, Obada A, Eric M. Scoping Review on Factors Associated with Continuity of Treatment among People Living with HIV in Nigeria. Biomedical Journal of Scientific & Technical Research. 2024; 57(3):49283-49292.
- 31.Kamenshchikova A, Peters CM, Nöstlinger C, Rice B, Ford N, Ravasi G, Burns F, Parczewski M, Hoebe CJ, Dukers N, Seedat F. Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis. The Lancet HIV. 2024; 11(12):e873-884.
- 32.Joseph P, Sun R, Guiteau C, Juste MA, Dorvil N, Vilbrun S, Secours R, Severe K, Raymond P, Cetoute F, Baptiste WJ. Continuity of care during severe civil unrest with a model of community-based HIV care: a retrospective cohort study from Haiti. The Lancet Regional Health–Americas. 2024; 37.
- 33.Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024; 2(3):14-26.
- 34.Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. Biochemical Alterations in Adult HIV Patients on Antiretroviral Therapy. World Journal of Pharmacy and Pharmaceutical Sciences. 2015; 4(3):153-160.
- 35.Boakye DS, Kumah E, Adjorlolo S. The fight for an AIDS-free world: confronting the stigma, reaching the marginalized. Annals of Global Health. 2024; 90(1).

36. Endalamaw A, Gilks CF, Ambaw F, Shiferaw WS, Assefa Y. Explaining inequity in knowledge, attitude, and services related to HIV/AIDS: a systematic review. *BMC Public Health*. 2024; 24(1):1815.
37. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018; 4(2):104-118.
38. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*. 2022; 2 (3): 128-134
39. Mustanski B, Queiroz A, Merle JL, Zamantakis A, Zapata JP, Li DH, Benbow N, Pyra M, Smith JD. A systematic review of implementation research on determinants and strategies of effective HIV interventions for men who have sex with men in the United States. *Annual review of psychology*. 2024; 75(1):55-85.
40. Idiong HM, Ekanem AM, Nwanja E, Idiong PE, Udofia EA. An assessment of the implementation of the HIV workplace policy in Akwa Ibom State: a cross-sectional descriptive study. *BMC Health Services Research*. 2025; 25(1):459.
41. Mody A, Sohn AH, Iwuji C, Tan RK, Venter F, Geng EH. HIV epidemiology, prevention, treatment, and implementation strategies for public health. *The Lancet*. 2024; 403(10425):471-492.
42. Wulandari LP, Lubis DS, Kurniati DP, Sumintang K, Ardrini DA, Mariani P, Januraga PP, Camellia A, Laksmi NM, Mahmudah L, Ong JJ. Challenges to integrating programs for the elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B into antenatal care: Experiences from Indonesia. *PLOS Global Public Health*. 2024; 4(3):e0002977.
43. Obeagu EI, Akinleye CA. Promoting social integration: blood transfusions and improved social well-being in HIV patients. *Elite Journal of Public Health*. 2024; 2(7):25-34.
44. Beecroft A, Vaikla O, Pant Pai N. Digital HIV self-testing as an exemplar: a perspective on benefits, challenges, and opportunities. *Expert Review of Molecular Diagnostics*. 2024; 24(10):913-925.
45. Cuadros DF, Huang Q, Mathenjwa T, Gareta D, Devi C, Musuka G. Unlocking the potential of telehealth in Africa for HIV: opportunities, challenges, and pathways to equitable healthcare delivery. *Frontiers in Digital Health*. 2024; 6:1278223.
46. O'Neil AM, Quinn KG, Algiers OH, John SA, Hirshfield S, Kallies KJ, Petroll AE, Walsh JL. Telehealth challenges, opportunities, and policy recommendations for rural older adults living with HIV in the United States. *Journal of Aging & Social Policy*. 2024:1-9.
47. Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, Thompson MA, Bedimo RJ, Benson CA, Buchbinder SP, Crabtree-Ramirez BE. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society–USA panel. *Jama*. 2025; 333(7):609-628.
48. Del Castillo JG, Elias MJ, Miguens I, Espinosa B, Juárez R, Lozoya LP, Trenc P, Manzanares JA, Marchena MJ, Rodríguez R, Cabrera N. Decalogue to promote the implementation and improvement of recommendations for the early diagnosis of HIV in Emergency Departments.

Enfermedades infecciosas y microbiología clínica (English ed.). 2024; 42(5):267-271.

49. Agaba CD, Namuli A, Ainomugisha B, Tibaijuka L, Ninsiima M, Ngonzi J, Akatukwasa C, Owaraganise A. Providers and women's perspectives on opportunities, challenges and recommendations to improve cervical cancer screening in women living with HIV at Mbarara Regional Referral Hospital: a qualitative study. BMC Women's Health. 2024; 24(1):392.

